China Kanghui Holdings to Report Second Quarter 2012 Financial Results

-- Company to Hold Conference Call on August 22, 2012 at 8:00 am ET --

CHANGZHOU, China, July 30, 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced that the Company plans to release second quarter 2012 financial results on Wednesday, August 22, 2012, before the market opens.

Kanghui will hold a corresponding conference call and live webcast at 8:00 a.m. ET (8:00 p.m. Beijing Time) on Wednesday, August 22, 2012 to discuss second quarter 2012 results and answer questions from investors. Listeners may access the call by dialing:

US Toll Free: 

1-866-519-4004

US Toll/International: 

1-718-354-1231

Hong Kong Toll Free: 

800-930-346

Hong Kong Toll: 

852-2475-0994

China Toll Free: 

800-819-0121

China Toll Free (Mobile): 

400-620-8038

Conference ID: 

12464049

A replay of the webcast will be accessible through August 29, 2012 on http://ir.kanghui.com or by dialing:

United States toll free: 

+1-866-214-5335

US Toll/International: 

+1-718-354-1232

Passcode:

12464049

About China Kanghui Holdings

Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma and spine, and has an extensive nationwide network of distributors for its products in China, as well as in 29 other countries. Kanghui has strong research and development capabilities, focused on developing new proprietary products and product lines, and enhancing existing products and product lines. For more information, please visit www.kanghui.com.

Contact:

China Kanghui Holdings Investor Relations Department 
+1-888-321-2558

Asia Bridge Capital Limited
Wendy Sun
+86-10-8556-9033
[email protected]

SOURCE China Kanghui Holdings

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.